B淋巴细胞刺激因子及其受体在狼疮性肾炎中的研究现状

doi:10.3969/j.issn.1004-583X.2024.05.016

摘要/Abstract

摘要：

狼疮性肾炎(lupus nephritis,LN)是系统性红斑狼疮(systemic lupus erythematosus,SLE)最常见的并发症,同时也是引起患者死亡的重要原因之一。B淋巴细胞刺激因子(B-cell activating factor,BAFF)在B细胞生长、发育和分化中具有重要的免疫调节作用,BAFF过度表达与SLE、类风湿性关节炎、干燥综合征等自身免疫性疾病的发生发展密切相关;BAFF会导致自身抗体产生和免疫复合物在肾脏沉积,参与LN的发病过程。近年来针对血清BAFF在LN临床诊断、病情评估及相关治疗方面显示出可喜的应用前景,现就BAFF在LN中的相关研究现状做一综述。

关键词: 红斑狼疮, 系统性, 狼疮性肾炎, B淋巴细胞刺激因子, B淋巴细胞刺激因子受体

中图分类号:

R593.241

陈彩合, 马淑燕, 黄文辉. B淋巴细胞刺激因子及其受体在狼疮性肾炎中的研究现状[J]. 临床荟萃, 2024, 39(5): 475-480.

导出引用管理器 EndNote|Ris|BibTeX

链接本文: https://huicui.hebmu.edu.cn/CN/10.3969/j.issn.1004-583X.2024.05.016

https://huicui.hebmu.edu.cn/CN/Y2024/V39/I5/475

参考文献 41

[1]	Tanaka Y. Systemic lupus erythematosus[J]. Best Pract Res Clin Rheumatol, 2022, 36(4): 101814.
[2]	中国狼疮肾炎诊断和治疗指南[J]. 中华医学杂志, 2019, (44): 3441-55.
[3]	张辉, 杨念生, 鲁静, 等. 狼疮肾炎诊疗规范[J]. 中华内科杂志, 2021, 60(9): 784-90.
[4]	Moore PA, Belvedere O, Orr A, et al. BLyS: member of the tumor necrosis factor family and B lymphocyte stimulator[J]. Science, 1999, 285(5425): 260-263. doi: 10.1126/science.285.5425.260 pmid: 10398604
[5]	Mukhopadhyay A, Ni J, Zhai Y, et al. Identification and characterization of a novel cytokine, THANK, a TNF homologue that activates apoptosis, nuclear factor-kappaB, and c-Jun NH2-terminal kinase[J]. Biol Chem, 1999, 274(23): 15978-15981.
[6]	Schneider P, Mackay F, Steiner V, et al. BAFF, a novel ligand of the tumor necrosis factor family, stimulates B cell growth[J]. Exp Med, 1999, 189(11): 1747-1756.
[7]	Shu HB, Hu WH, Johnson H. TALL-1 is a novel member of the TNF family that is down-regulated by mitogens[J]. J Leukoc Bio1, 1999, 65(5): 680-683.
[8]	Goodman DB, Azimi CS, Kearns K, et al. Pooled screening of CAR T cells identifies diverse immune signaling domains for next-generation immunotherapies[J]. Sci Transl Med, 2022, 14(670): eabm1463.
[9]	Smulski CR, Eibel H. BAFF and BAFF-Receptor in B Cell Selection and Survival[J]. Front Immunol, 2018, 9: 2285. doi: 10.3389/fimmu.2018.02285 pmid: 30349534
[10]	Meinl E, Krumbholz M. Endogenous soluble receptors sBCMA and sTACI: Biomarker, immunoregulator and hurdle for therapy in multiple myeloma[J]. Curr Opin Immunol, 2021, 71:117-123. doi: 10.1016/j.coi.2021.06.015 pmid: 34330018
[11]	Deng C, Lo T, Chan K, et al. Role of B lymphocytes in the pathogenesis of NAFLD: A 2022 update[J]. Int J Mol Sci, 2022, 23(20): 12376.
[12]	Steines L, Poth H, Herrmann M, et al. B cell activating factor (BAFF) is required for the development of intra-renal tertiary lymphoid organs in experimental kidney transplantation in rats[J]. Int J Mol Sci. 2020, 21(21):8045.
[13]	Schwarting A, Relle M, Meineck M, et al. Renal tubular epithelial cell-derived BAFF expression mediates kidney damage and correlates with activity of proliferative lupus nephritis in mouse and men[J]. Lupus, 2018, 27(2): 243-256. doi: 10.1177/0961203317717083 pmid: 28659046
[14]	Schweighoffer E, Tybulewicz VL. BAFF signaling in health and disease[J]. Curr Opin Immunol, 2021, 71: 124-131. doi: 10.1016/j.coi.2021.06.014 pmid: 34352467
[15]	Vincent F, Kandane-Rathnayake R, Koelmeyer R, et al. Analysis of serum B cell-activating factor from the tumor necrosis factor family (BAFF) and its soluble receptors in systemic lupus erythematosus[J]. Clin Transl Immunology, 2019, 8(4): e01047.
[16]	Stohl W, Yu N, Wu Y. B cell and t cell dissimilarities in baff-deficient versus br3-deficient c57bl/6 mice[J]. J Immunol, 2022, 209(11): 2133-2140. doi: 10.4049/jimmunol.2200620 pmid: 36426969
[17]	Atisha-Fregoso Y, Toz B, Diamond B. Meant to B: B cells as a therapeutic target in systemic lupus erythematosus[J]. J Clin Invest, 2021, 131(12) :e149095.
[18]	Itotagawa E, Tomofuji Y, Kato Y, et al. SLE stratification based on baff and ifn-i bioactivity for biologics and implications of baff produced by glomeruli in lupus nephritis[J]. Rheumatology (Oxford), 2023, 62(5): 1988-1997.
[19]	Marín-Rosales M, Palafox-Sánchez CA, Franco-Topete RA, et al. Renal tissue expression of baff and baff receptors is associated with proliferative lupus nephritis[J]. J Clin Med, 2022, 12(1):71.
[20]	Steri M, Orrù V, Idda M, et al. Overexpression of the cytokine baff and autoimmunity risk[J]. N Engl J Med, 2017, 376(17): 1615-1626.
[21]	Friebus-Kardash J, Trendelenburg M, Eisenberger U, et al. Susceptibility of baff-var allele carriers to severe sle with occurrence of lupus nephritis[J]. BMC Nephrol, 2019, 20(1): 430. doi: 10.1186/s12882-019-1623-4 pmid: 31752784
[22]	Fasano S, Milone A, Nicoletti G F, et al. Precision medicine in systemic lupus erythematosus[J]. Nat Rev Rheumatol, 2023, 19(6): 331-342. doi: 10.1038/s41584-023-00948-y pmid: 37041269
[23]	Zaki Dsd AN, Mohammed ZAZ. Study of b cell activating factor (baff) and baff-r in systemic lupus erythematosus patients[J]. Am J Med Sci, 2019, 9(6): 203-209.
[24]	Sanchez E, Smith EJ, Yashar MA, et al. The role of b-cell maturation antigen in the biology and management of, and as a potential therapeutic target in, multiple myeloma[J]. Targeted Oncology, 2018, 13(1): 39-47. doi: 10.1007/s11523-017-0538-x pmid: 29230672
[25]	Salazar-Camarena DC, Ortíz-Lazareno P, Marín-Rosales M, et al. Baff-r and taci expression on cd3+ t cells: interplay among baff, april and t helper cytokines profile in systemic lupus erythematosus[J]. Cytokine, 2019, 114: 115-127. doi: S1043-4666(18)30420-4 pmid: 30467093
[26]	Ortiz-Aljaro P, Montes-Cano MA, García-Lozano JR, et al. Protein and functional isoform levels and genetic variants of the baff and april pathway components in systemic lupus erythematosus[J]. Sci Rep, 2022, 12(1): 11219. doi: 10.1038/s41598-022-15549-0 pmid: 35780200
[27]	Kang S, Fedoriw Y, Brenneman E, et al. Baff induces tertiary lymphoid structures and positions t cells within the glomeruli during lupus nephritis[J]. J Immunol, 2017, 198(7): 2602-2611. doi: 10.4049/jimmunol.1600281 pmid: 28235864
[28]	Suso J, Posso-Osorio I, Jiménez C, et al. Profile of baff and its receptors' expression in lupus nephritis is associated with pathological classes[J]. Lupus, 2018, 27(5): 708-715. doi: 10.1177/0961203317739132 pmid: 29087261
[29]	Vincent F, Kandane-Rathnayake R, Hoi A, et al. Urinary b-cell-activating factor of the tumour necrosis factor family (baff) in systemic lupus erythematosus[J]. Lupus, 2018, 27(13): 2029-2040. doi: 10.1177/0961203318804885 pmid: 30301439
[30]	Wallace D, Stohl W, Furie R, et al. A phase II, randomized, double-blind, placebo-controlled, dose-ranging study of belimumab in patients with active systemic lupus erythematosus[J]. Arthritis Rheum, 2009, 61(9): 1168-1178.
[31]	Navarra SV, Guzmán RM, Gallacher AE, et al. Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: A randomised, placebo-controlled, phase 3 trial[J]. Lancet, 2011, 377(9767): 721-731. doi: 10.1016/S0140-6736(10)61354-2 pmid: 21296403
[32]	Furie R, Petri M, Zamani O, et al. A phase III, randomized, placebo-controlled study of belimumab, a monoclonal antibody that inhibits B lymphocyte stimulator, in patients with systemic lupus erythematosus[J]. Arthritis Rheum, 2011, 63(12): 3918-3930.
[33]	Zhang F, Bae S, Bass D, et al. A pivotal phase III, randomised, placebo-controlled study of belimumab in patients with systemic lupus erythematosus located in China, Japan and South Korea[J]. Ann Rheum Dis, 2018, 77(3): 355-363. doi: 10.1136/annrheumdis-2017-211631 pmid: 29295825
[34]	Furie R, Rovin B H, Houssiau F, et al. Two-year, randomized, controlled trial of belimumab in lupus nephritis[J]. N Engl J Med, 2020, 383(12): 1117-1128.
[35]	Atisha-Fregoso Y, Malkiel S, Harris KM, et al. Phase II randomized trial of rituximab plus cyclophosphamide followed by belimumab for the treatment of lupus nephritis[J]. Arthritis Rheumatol, 2021, 73(1): 121-131.
[36]	Kidney Disease: Improving Global Outcomes (KDIGO) Glomerular Diseases Work Group. Kdigo 2021 clinical practice guideline for the management of glomerular diseases[J]. Kidney Int, 2021, 100(4s): S1-S276. doi: 10.1016/j.kint.2021.05.021 pmid: 34556256
[37]	Furie RA, Leon G, Thomas M, et al. A phase 2, randomised, placebo-controlled clinical trial of blisibimod, an inhibitor of B cell activating factor, in patients with moderate-to-severe systemic lupus erythematosus, the pearl-sc study[J]. Ann Rheum Dis, 2015, 74(9): 1667-1675. doi: 10.1136/annrheumdis-2013-205144 pmid: 24748629
[38]	Merrill JT, Shanahan WR, Scheinberg M, et al. Phase III trial results with blisibimod, a selective inhibitor of B-cell activating factor, in subjects with systemic lupus erythematosus (sle): results from a randomised, double-blind, placebo-controlled trial[J]. Ann Rheum Dis, 2018, 77(6): 883-889. doi: 10.1136/annrheumdis-2018-213032 pmid: 29563108
[39]	Wallace DJ, Isenberg DA, Morand EF, et al. Safety and clinical activity of atacicept in the long-term extension of the phase 2b address II study in systemic lupus erythematosus[J]. Rheumatology (Oxford), 2021, 60(11): 5379-5389. doi: 10.1093/rheumatology/keab115 pmid: 33547784
[40]	Isenberg D, Gordon C, Licu D, et al. Efficacy and safety of atacicept for prevention of flares in patients with moderate-to-severe systemic lupus erythematosus (SLE): 52-week data (april-sle randomised trial)[J]. Ann Rheum Dis, 2015, 74(11): 2006-2015. doi: 10.1136/annrheumdis-2013-205067 pmid: 24951103
[41]	Wu D, Li J, Xu D, et al. A Human recombinant fusion protein targeting B lymphocyte stimulator (BlyS) and a proliferation-inducing ligand (APRIL), telitacicept (RC18), in systemic lupus erythematosus (SLE): Results of a phase 2b study[C]// Arthritis & Rheumatology. 111 River St, Hoboken 07030-5774, NJ USA: WILEY, 2019, 71.

B淋巴细胞刺激因子及其受体在狼疮性肾炎中的研究现状

RichHTML

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献 41

相关文章 1

编辑推荐

Metrics

本文评价